Hoya Vision Care has shared the latest findings of the clinical application of the MiYOSMART spectacle lens, and its role in myopia management, at the International Myopia Conference (IMC), held 4–7 September 2022 in Rotterdam, The Netherlands. During a myopia symposium, hosted by Hoya, renowned key opinion leaders shared new European data and discussed topics including emmetropic eye growth, combination treatment and relative peripheral refraction (RPR).

Dr Andrea Lembo, from the University Hospital San Giuseppe Multimedica in Milan, Italy, shared the results of a clinical application of the MiYOSMART spectacle lens in combination with 0.01% Atropine drops in European myopic children and adolescents, demonstrating that over one-year, axial elongation and myopia progression were reduced with maximum effect using the combination treatment.1

Further to this, Professor Hakan Kaymak, from the Internationale Innovative Ophthalmochirurgie in Duesseldorf, Germany, presented findings of his study on axial length growth under treatment with MiYOSMART spectacle lenses. The data of German children wearing MiYOSMART spectacle lenses reconfirmed previous clinical study results, with further findings showing that children adapt very well to MiYOSMART spectacle lenses, with no safety concerns even in combination with low-dose atropine.1

Professor Carly Lam, from The Hong Kong Polytechnic University, shared how myopia control effect may be influenced by baseline relative peripheral refraction in children wearing the MiYOSMART spectacle lens with D.I.M.S. Technology.1The results showed that myopia control effect was stronger in children with baseline hyperopic RPR than in children with baseline myopic RPR. 1

References available at mivision.com.au